$73.1 Million

Inozyme Pharma

Bookrunner, April 2022

Registered Direct Offering

Inozyme Pharma, Inc. (the “Company”) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through the Company’s in-depth understanding of the biological pathways involved in mineralization, they are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The Company is initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

More Like This

Apr 2022
$225 Million

Senior Secured Term Loan

Sole Placement Agent & Exclusive Financial Advisor

View Details
Apr 2022
Proven Behavior Solutions Logo

Strategic Investment From Health Enterprise Partners

Exclusive Financial Advisor

View Details
Apr 2022

Majority Stake in FotoFinder Systems GmbH

M&A and Debt Advisor

View Details